SB269652 is primarily used in pharmacological research as a selective antagonist for the dopamine D3 receptor. Its application is significant in studying the role of D3 receptors in the central nervous system, particularly in relation to neurological and psychiatric disorders. Researchers utilize SB269652 to explore potential treatments for conditions such as schizophrenia, Parkinson's disease, and addiction. By blocking D3 receptors, it helps in understanding the receptor's function and its impact on behavior, cognition, and motor control. This compound is also valuable in developing new therapeutic agents that target dopamine receptors with higher specificity and fewer side effects.